AbbVie announced that a Phase 2 trial of venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion.
The Phase 2, multicenter, international, open label clinical trial was designed to evaluate the efficacy and safety of venetoclax in CLL patients with 17p deletion who relapsed, were refractory to existing therapies, or who were previously not treated for their CLL. The primary efficacy endpoint is overall response rate.
Venetoclax is an oral selective B-cell lymphoma-2 (BCL-2) inhibitor being developed in collaboration with Genentech and Roche. In May 2015, it was granted Breakthrough Therapy designation for CLL in previously treated (relapsed/refractory) patients with the 17p deletion. It is currently being evaluated in Phase 3 trials for the treatment of relapsed/refractory CLL, along with studies in several other cancers.
For more information call (800) 633–9110 or visit AbbVie.com.